JYSELECA Market Drug Insight and Market Forecast - 2032

JYSELECA Market Drug Insight and Market Forecast − 2032

“JYSELECA Market Drug Insight and Market Forecast – 2032” report provides comprehensive insights about JYSELECA for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the JYSELECA for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the JYSELECA for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JYSELECA market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.

Drug Summary

JYSELECA (Filgotinib) is an orally bioavailable, investigational agent with potential anti-inflammatory and immunomodulating activities discovered and developed by Galapagos collaborating with Gilead. It is a selective JAK1 (Janus kinase 1) inhibitor. JAK1 is an enzyme with an essential role in promoting biologic responses induced by a subset of cytokine receptors, proteins that lead to inflammation. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling as JAK1 mediates signaling of many pro-inflammatory cytokines.

Dosage

The recommended dose for induction and maintenance treatment is 200 mg once daily. For patients with UC who do not show an adequate therapeutic benefit during the initial 10 weeks of treatment, 12 additional weeks of induction treatment with filgotinib 200 mg once daily may relieve symptoms. Patients who have not shown any therapeutic benefit after 22 weeks of treatment should discontinue filgotinib.

Mechanism of action

Filgotinib is adenosine triphosphate (ATP)—a competitive and reversible inhibitor of the JAK family. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane. JAK1 is important in mediating inflammatory cytokine signals, JAK2 in mediating myelopoiesis and erythropoiesis, and JAK3 plays critical roles in immune homeostasis and lymphopoiesis. JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) within the signaling pathway, which modulate intracellular activity, including gene expression. Filgotinib modulates these signaling pathways by preventing the phosphorylation and activation of STATs. In biochemical assays, filgotinib preferentially inhibited the activity of JAK1 and showed >fivefold higher potency of filgotinib for JAK1 over JAK2, JAK3, and TYK2. In human cellular assays, filgotinib preferentially inhibited JAK1/JAK3-mediated signaling downstream of the heterodimeric cytokine receptors for interleukin (IL)-2, IL-4, and IL-15, JAK1/2-mediated IL-6, and JAK1/TYK2-mediated type I interferons, with functional selectivity over cytokine receptors that signal via pairs of JAK2 or JAK2/TYK2. GS-829845, the primary metabolite of filgotinib, was approximately 10-fold less active than filgotinib in in vitro assays while exhibiting a similar JAK1 preferential inhibitory activity. In an in vivo rat model, the overall pharmacodynamics effect was predominantly driven by the metabolite.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the JYSELECA description, mechanism of action, dosage and administration, research and development activities in ulcerative colitis.

Elaborated details on JYSELECA regulatory milestones and other development activities have been provided in this report.

The report also highlights the JYSELECA research and development activities in ulcerative colitis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around JYSELECA.

The report contains forecasted sales of for ulcerative colitis till 2032.

Comprehensive coverage of the late-stage emerging therapies for ulcerative colitis.

The report also features the SWOT analysis with analyst views for JYSELECA in ulcerative colitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JYSELECA Analytical Perspective by DelveInsight

In-depth JYSELECA Market Assessment

This report provides a detailed market assessment of JYSELECA for ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

JYSELECA Clinical Assessment

The report provides the clinical trials information of JYSELECA for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for ulcerative colitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JYSELECA dominance.

Other emerging products for ulcerative colitis are expected to give tough market competition to JYSELECA and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JYSELECA in ulcerative colitis.

Our in-depth analysis of the forecasted sales data of JYSELECA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JYSELECA in ulcerative colitis.

Key Questions

What is the product type, route of administration and mechanism of action of JYSELECA?

What is the clinical trial status of the study related to JYSELECA in ulcerative colitis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JYSELECA development?

What are the key designations that have been granted to JYSELECA for ulcerative colitis?

What is the forecasted market scenario of JYSELECA for ulcerative colitis?

What are the forecasted sales of JYSELECA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to JYSELECA for ulcerative colitis?

Which are the late-stage emerging therapies under development for the treatment of ulcerative colitis?